文献速递MDS 与骨髓增殖性肿瘤白血病

CPX-351治疗低甲基化药物失败后Int-2或高危国际预后评分系统骨髓增生异常综合征及慢性粒单核细胞白血病的1/2期研究

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
PubMed 文献 · Br J Haematol · 2023-11-10

这项单中心1/2期研究评估了低剂量CPX-351在低甲基化药物失败的25例高危骨髓增生异常综合征或慢性粒单核细胞白血病患者中的安全性和初步活性,常见3-4级非血液学不良事件为发热性中性粒细胞减少(48%)和肺部感染(20%),总缓解率56%,数据提示低剂量CPX-351安全,需进一步研究评估其活性。

要点

  • 低剂量CPX-351在高危MDS/CMML低甲基化药物失败患者中显示安全性。
  • 总缓解率56%,中位无复发生存9.2个月,中位总生存8.7个月。
  • 75单位/m²剂量下3例年龄>75岁患者出现心脏毒性,后续在50单位/m²继续入组。

核心结论

  • 数据提示低剂量CPX-351是安全的,需进一步研究评估其活性。

研究设计与样本

  • 单中心1/2期研究,2019年6月至2023年6月入组25例低甲基化药物失败的高危骨髓增生异常综合征或慢性粒单核细胞白血病患者(1期n=15;2期n=10),其中高危骨髓增生异常综合征19例(76%),慢性粒单核细胞白血病6例(24%)。
  • CPX-351设10、25、50和75单位/m²四个剂量,诱导期第1、3、5天给药,巩固期第1、3天给药。

主要发现

  • 最常见的3-4级非血液学治疗中出现的不良事件为发热性中性粒细胞减少(n=12,48%)和肺部感染(n=5,20%)。
  • 75单位/m²剂量下3例年龄>75岁患者出现心脏毒性,后续在50单位/m²继续入组。
  • 4周和8周死亡率分别为0%和8%。
  • 总缓解率56%,中位无复发生存9.2个月(95%CI 3.2-15.1个月),中位总生存8.7个月(95%CI 1.8-15.6个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Failure after hypomethylating agents (HMAs) is associated with dismal outcomes in higher risk myelodysplastic syndromes (HR-MDS) or chronic myelomonocytic leukaemia (CMML). We aimed to evaluate the safety and preliminary activity of lower doses of CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, in a single-centre, phase 1/2 study for patients with HR-MDS or CMML after HMA failure. Four doses of CPX-351 (10, 25, 50 and 75 units/m2 ) administered on Days 1, 3 and 5 of induction and Days 1 and 3 of consolidation were evaluated. Between June 2019 and June 2023, 25 patients were enrolled (phase 1: n = 15; phase 2: n = 10) including 19 (76%) with HR-MDS and 6 (24%) with CMML. Most common grade 3-4 non-haematological treatment-emergent adverse events were febrile neutropenia (n = 12, 48%) and lung infection (n = 5, 20%). Three patients (age >75) experienced cardiac toxicity at the 75 units/m2 dose. Further enrolment continued at 50 units/m2 . Four- and 8-week mortality were 0% and 8% respectively. The overall response rate was 56% with median relapse-free and overall survivals of 9.2 (95% CI 3.2-15.1 months) and 8.7 months (95% CI 1.8-15.6 months) respectively. These data suggest that lower doses of CPX-351 are safe. Further studies are needed to evaluate its activity.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Montalban-Bravo G, Jabbour E, Borthakur G, et al. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2023. PMID: 37946611. doi:10.1111/bjh.19193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。